M&A

ANI Pharmaceuticals bids about $560M for rare disease drugmaker Egetis

ANI Pharmaceuticals made a recommended cash offer for Egetis Therapeutics at SEK 11.25 a share, valued near $560 million. Egetis sells EMCITATE for MCT8 deficiency, which ANI expects could top $300 million in peak annual sales. Holders of about 42% of shares back the deal, which needs 90% acceptance and regulatory clearance.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call